Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Biological atlas and tissue collection for severe obesity

Official title: Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)

Run by University Hospital, Lille · NCT01129297 · Data updated 2026-11-12

This project will collect blood and tissue samples from adults having abdominal surgery to test how obesity and diabetes change gene activity in tissues that control glucose and fat.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment20000 (estimated)
SponsorUniversity Hospital, Lille
Academic / other
Locations1 site (Lille, Nord)
StatusRecruiting
StartedJune 13, 2006
Main results expectedJune 2027
Study endsJune 2027
Registry record updatedDecember 8, 2025
Trial IDNCT01129297 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 who are undergoing abdominal surgery (for example bariatric surgery, cholecystectomy, or parietal repair) and meet one of the four BMI/glucose-tolerance phenotype categories are ideal candidates.

Probably not a fit

People who are not having abdominal surgery or who fall outside the age, BMI, or glucose-tolerance criteria are unlikely to be eligible or to receive direct benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort collects blood and surgical tissue samples from adults undergoing abdominal operations to study gene expression in tissues involved in glucose and lipid metabolism. Participants are placed into four phenotype groups by BMI and glucose tolerance (severe obesity with diabetes, severe obesity with glucose intolerance, severe obesity without diabetes, and normal-weight controls). The project uses whole-genome linkage, transcriptomics, and bioinformatics and compares human findings with relevant animal models to map genetic variants and affected pathways. Samples and linked clinical data will create a biological atlas of “diabesity” to support mechanistic and therapeutic research.

Why it matters

Potential benefit: If successful, the work could reveal gene-expression patterns and pathways that point to better-targeted treatments or prevention strategies for people with obesity-related diabetes.

How similar studies have gone: Other tissue biobanks and transcriptomic studies have previously identified gene-expression signatures linked to obesity and type 2 diabetes, so the general approach has produced useful insights though this integrated genomics-to-pathway atlas is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 18 and 65 years
* Indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical
* Phenotype corresponding to one of the following four cases :

  1. Body Mass Index ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
  2. Body Mass Index ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/L and \<7 mmol/l and/or\> 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
  3. Body Mass Index ≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
  4. Body Mass Index \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)

5)27 \<Body Mass Index \<35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)

Exclusion Criteria:

* unable to receive clear information
* refusal to sign the consent form
* pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue

Where it's running

  • Lille University Hospital
    Lille, Nord, France
    Recruiting

Study contacts

  • Principal investigator: Francois PATTOU, MD PhD — University Hospital, Lille
  • Study coordinator: Francois PATTOU, MD PhD
  • Email: fpattou@univ-lille2.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.